Strategic license deal with ProMetic Life Sciences

UMEÅ, SWEDEN – November 12, 2015 – Omnio AB ( announced today that it has entered into a strategic research and development agreement with the Canadian biopharmaceutical company ProMetic Life Sciences Inc. Under the licence agreement ProMetic and Omnio will combine their unique knowhow to develop the plasma protein plasminogen into a ’’Biologics product’’ that speeds up the healing of otherwise very hard-to-treat wounds including diabetic foot ulcers.

Read the full press release

Swedish version

Comments are closed.